Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Design Therapeutics Inc

DSGN ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$14.83

▲ +3.06%

Market Cap $928.09M · Vol 87.49K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$928.09M

Small Cap

Div Yield

N/A

EPS Growth

-11.01%

YoY

RSI (14)

83.60

Momentum

Beta

1.67

vs Market

52W High

$17.20

13.78% below

52W Low

$4.68

216.88% above

Volume

87.49K

Avg 188.08K

P/B

2.67

Price-to-book

ROE

N/A

Return on equity

Free Float

68.26%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Design Therapeutics Inc (DSGN) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does DSGN pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+6.00%

+8.49%

+1.99%

+47.27%

YTD

+58.10%

+187.40%

+584.99%

-10.18%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-69,792,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-29.18% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	2.67
P/FCF	N/A
EPS Growth	-11.01%
Outstanding Shares	62.58M

Technical Indicators

50-Day SMA	$12.99
200-Day SMA	$11.02
RSI (14)	83.60
Beta	1.67
52-Week High	$17.20
52-Week Low	$4.68

Volume Today	87.49K
Avg Daily Volume (30D)	188.08K
Relative Volume	0.47x
Volatility (10D)	26.95
Volatility (30D)	52.54
Free Float	68.26%

Analyst Consensus

BUY

Current Price $14.83

Mean Target $21.00

52W Low$4.68 52W High$17.20

Current

Target

$4.68 $17.20

Current Analyst target

+41.60% upside potential · 7 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00SNC49W7

ISINUS25056L1035

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 3, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. It is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its Huntington's Disease program is focused on the development of a potentially disease-modifying treatment for HD.